1000 SPRING ST, SILVER SPRING, MD
Reports Second Quarter 2026 Financial Results
Announces Appointment of Victor Dzau to its Board of Directors
Shareholders Approve 2026 Stock Incentive Plan at Annual Meeting
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
Investor Presentation
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
S-8 POS